AMLX — Amylyx Pharmaceuticals Income Statement
0.000.00%
Last trade - 00:00Annual income statement for Amylyx Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.285 | 22.2 | 381 | 87.4 | 0 |
| Cost of Revenue | |||||
| Gross Profit | — | 19.2 | 355 | 55.2 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 83 | 224 | 342 | 402 | 153 |
| Operating Profit | -82.7 | -201 | 38.8 | -315 | -153 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -87.9 | -198 | 54.3 | -302 | -145 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -87.9 | -198 | 49.3 | -302 | -145 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -87.9 | -198 | 49.3 | -302 | -145 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -87.9 | -198 | 49.3 | -302 | -145 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.56 | -3.39 | 0.704 | -2.8 | -1.53 |